1. Scrip
  2. >>R&D

Lilly Doubles Down On Novel Pain Drugs With Confo Therapeutics Deal

Adds To Three Non-Opioid Candidates In Pipeline

 
• By Andrew McConaghie

Belgium’s Confo Therapeutics gains its first big pharma partner in the field of non-opioid pain treatment, giving the big pharma will test its master protocol approach as it put its R&D muscle behind this major area of unmet need.

Eli Lilly logo sign atop Lilly Biotechnology Center
The deal means that Lilly now has four candidates in development against pain. • Source: Michael Vi / Shutterstock.com

Eli Lilly is determined to be a key player in a future non-opioid pain treatment market, and has in-licensed a novel oral compound from Belgium’s Confo Therapeutics, paying $40m upfront in a deal worth up to $590m.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Veraxa Takes SPAC Route To Develop Bispecific ADCs and T-Cell Engagers

 
• By Andrew McConaghie

The Swiss biotech firm could go public on the NASDAQ later this year, and points to other preclinical dealmaking in the space to back its strategy.

Pipeline Watch: Eight Approvals And Three Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

In Brief: Synthetic Design Lab Debuts With $20m To Advance Cutting-Edge ADCs

 
• By Sushmita Panda

As ADCs continue to be a growth area globally, a new US-based venture with novel platform technology has emerged from stealth mode with $20m in funding.